Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

Exonate Ltd. (the Company), an mRNA therapy company focused on treatments for diabetic complications, today announced its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a ...

The National Institute for Health and Care Excellence (NICE) has today published final draft guidance recommending a new treatment for people with diabetic macular oedema (DMO). DMO is the most common ...

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the data from a successful Phase Ib/IIa ...

Since February 2015, aflibercept (trade name Eylea) has been available also for patients with impaired vision due to macular oedema that follows blockage of branch veins of the central retinal vein ...

March 26, 2007 – New York, NY -- The Juvenile Diabetes Research Foundation, the world’s largest charitable funder of type 1 diabetes research, announced that the Ranibizumab for Edema of the mAcula in ...

Justine R. Smith receives funding from Macular Disease Foundation Australia, Queensland Eye Institute Foundation, Flinders Foundation and the National Health and Medical Research Council of Australia.

The National Institute for Health and Care Excellence (NICE) has recommended a new treatment option for people with diabetic macular oedema (DMO) with thousands of people set to benefit from the ...